Aging News & Information
War Against Aging Heats Up with Calico, AbbVie Joint
to create leading R&D facility in San Francisco focused on aging,
4, 2014 There was a major announcement in the war against aging
yesterday as Calico, the Google-backed life sciences company, and AbbVie,
a global, research-based biopharmaceutical company, announced a
collaboration to discover, develop and bring to market new therapies for
patients with age-related diseases, including neurodegeneration and
The agreement also paves the way for Calico to
establish a "world-class" research and development facility in the San
Francisco Bay Area, according to the statement.
Calico is led by Arthur D. Levinson Ph.D. (former
chairman and CEO of Genentech) and
Hal V. Barron, M.D. (former Executive Vice President and
Chief Medical Officer of Genentech).
Under the agreement, the companies will combine
their complementary strengths to accelerate the availability of new
therapies for age-related diseases:
. Calico will use its scientific expertise
to establish a world-class research and development facility, with a
focus on drug discovery and early drug development
. AbbVie will provide scientific and
clinical development support and its commercial expertise to bring new
discoveries to market
"This collaboration demonstrates our commitment to
exploring new areas of medicine and innovative approaches to drug
discovery and development that augments our already robust pipeline,"
Richard A. Gonzalez, Chairman of the Board and Chief
Executive Officer, AbbVie.
"We are pleased to be working with such outstanding
Hal Barron and their team. The potential to help improve
patients' lives with new therapies is enormous."
"Our relationship with AbbVie is a pivotal event
for Calico, whose mission is to develop life-enhancing therapies for
people with age-related diseases. It will greatly accelerate our
efforts to understand the science of aging, advance our clinical work,
and help bring important new therapies to patients everywhere," said
Art Levinson, CEO and founder of Calico.
Read the latest news on
Details of the Research Collaboration
AbbVie and Calico will each initially provide up to $250 million
to fund the collaboration with the potential for both sides to
contribute an additional $500 million
Calico will be responsible for research and early development
during the first five years and continue to advance collaboration
projects through Phase 2a for a ten year period
AbbVie will support Calico in its early R&D efforts and,
following completion of Phase 2a studies, will have the option to manage
late-stage development and commercial activities
Both parties will share costs and profits equally
"We are thrilled to have the opportunity to work
with the many outstanding scientists at AbbVie to ensure that the
important science at Calico is advanced quickly to benefit patients,"
said Hal Barron, M.D., President of Research and Development at Calico.
"We are extremely proud to have our research teams
partnering with Calico as we aim to address treatments for diseases of
aging," said Michael Severino, M.D., Executive Vice President, Research
and Development, and Chief Scientific Officer, AbbVie.
"Our broad R&D experience and capabilities will
complement Calico's biotechnology expertise and innovative scientific
approaches. Together, we are confident that we will bring new
therapeutic solutions to patients."
Calico expects to begin filling critical positions
immediately and plans to establish a substantial team of scientists and
research staff in the San Francisco Bay Area.
AbbVie is a global, research-based biopharmaceutical company formed
in 2013 following separation from Abbott Laboratories. The company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of
the world's most complex and serious diseases. AbbVie employs
approximately 25,000 people worldwide and markets medicines in more than
170 countries. For further information on the company and its people,
portfolio and commitments, please visit
on Twitter or view careers on our
Calico (California Life Sciences LLC) is a Google-founded research
and development company whose mission is to harness advanced
technologies to increase our understanding of the biology that controls
lifespan. We will use that knowledge to devise interventions that enable
people to lead longer and healthier lives. Visit
Financial Relief for Volkswagen Diesel Owners
You may be eligible for money damages if you owned or leased one of these VW, Porsche or Audi vehicles.
In the major scandal of 2015, Volkswagen cheated you and the world. They rigged diesel emission controls so you, nor regulators, would know how much pollution their cars were adding to our environment.
They were caught and have reserved $7.3 billion to help "make it right" with victims.
If you owned or leased one of these vehicles, contact us now.
Janicek Law attorneys are actively pursuing these cases against VW. Do Not Wait...
Janicek Law Firm, PC
(Call toll free)
VW Jetta SportWagen (20092014)
VW Golf (2010-2015)
VW Golf SportWagen (2015)
VW Beetle (20122015)
VW Passat (2012-2015)
Audi A3 (2010-2015)
VW Touareg (20092016)
Porsche Cayenne (2015)
Audi A6, A7, A8, Q5 Quattro (2016)